Clinical Trial Update: Study of Efficacy and Safety of Omalizumab in Refractory Chronic Spontaneous Urticaria Patients [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating the efficacy and safety of omalizumab in patients with refractory chronic spontaneous urticaria has completed, with results posted in…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Spontaneous Urticaria

Drugs mentioned

• Omalizumab (Omalizumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Chronic Spontaneous Uriticaria | Phase 3 | Status: COMPLETED | Results posted: 2016-09-20